| 1 |
28947565 | NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. | 2018 Mar 1 |
16 |
| 2 |
29284705 | Immunotherapy of Myelodysplastic Syndrome: You Can Run, but You Can't Hide. | 2018 Mar 1 |
2 |
| 3 |
28677424 | Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy. | 2017 Jul |
1 |
| 4 |
29088766 | Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. | 2017 Sep 26 |
1 |
| 5 |
26330563 | Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. | 2016 Mar |
3 |
| 6 |
26883197 | Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. | 2016 Mar 15 |
2 |
| 7 |
26447882 | Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing. | 2015 |
2 |
| 8 |
24535937 | Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. | 2014 Jan |
2 |
| 9 |
25260825 | Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. | 2014 Nov |
1 |
| 10 |
23266925 | Complete remission following decitabine/dendritic cell vaccine for relapsed neuroblastoma. | 2013 Jan |
1 |
| 11 |
22306901 | Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. | 2012 Feb-Mar |
1 |
| 12 |
21626030 | MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. | 2011 Sep |
4 |
| 13 |
22060015 | Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway. | 2011 Nov 7 |
4 |
| 14 |
20381863 | The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. | 2010 Jul |
1 |
| 15 |
20480522 | Effect of 5-aza-2'-deoxycytidine on immune-associated proteins in exosomes from hepatoma. | 2010 May 21 |
1 |
| 16 |
18677478 | Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. | 2009 Mar |
1 |
| 17 |
19030781 | Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells. | 2009 Mar |
1 |
| 18 |
18240144 | The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. | 2008 Jun 1 |
1 |
| 19 |
18519754 | Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. | 2008 Jun 1 |
2 |
| 20 |
16140944 | Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. | 2005 Sep 1 |
2 |
| 21 |
11265773 | Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. | 2001 Mar-Apr |
4 |